Yes, ALS (amyotrophic lateral sclerosis) is officially classified as a rare disease in the United States. Roughly 33,000 Americans are living with ALS at any given time, which falls well below the legal threshold of 200,000 people that defines a rare disease under the Orphan Drug Act. This designation has real consequences for how ALS treatments get developed, funded, and approved.
How ALS Meets the Rare Disease Threshold
The FDA defines a rare disease as any condition affecting fewer than 200,000 people in the country. With an estimated 33,000 cases in the U.S. as of 2022, ALS comes in at roughly one-sixth of that cutoff. The CDC’s National ALS Registry projects cases will rise by more than 10% to over 36,000 by 2030, but that still keeps ALS firmly in rare disease territory.
Europe uses a different formula but reaches the same conclusion. The European Medicines Agency classifies a disease as rare if fewer than 5 in 10,000 people have it. ALS prevalence falls far below that line as well.
How Rare ALS Is Compared to Other Neurological Diseases
To put ALS in perspective, consider the neurological conditions most people are more familiar with. Multiple sclerosis affects roughly 1 million Americans. Parkinson’s disease affects close to 1 million as well. ALS, at 33,000, is roughly 30 times less common than either. All three diseases damage the nervous system, but ALS is in a different category when it comes to how many people it touches.
The lifetime risk for an average person developing ALS is about 0.3%, or roughly 1 in 330. That risk climbs to around 1.4% for first-degree relatives of someone with the disease.
What Rare Disease Status Means for Patients
ALS carries an official orphan drug designation from the FDA. This isn’t just a label. The Orphan Drug Act gives pharmaceutical companies financial incentives to develop treatments for rare conditions that might otherwise be too small a market to justify the investment. Those incentives include tax credits for clinical research, reduced regulatory fees, and seven years of market exclusivity once a drug is approved.
Without orphan designation, many of the ALS therapies currently in development would likely never have entered clinical trials. For a disease with no cure, those pipeline treatments represent the primary hope for extending survival.
Why Diagnosis Takes So Long
Rarity creates a practical problem: most doctors will never see a case of ALS in their careers, which makes it harder to recognize. The median time from first symptoms to a confirmed diagnosis is 11.5 months. During that window, patients typically see an average of three different physicians, and about 52% receive at least one incorrect diagnosis before ALS is identified.
The timeline breaks down roughly like this. People wait a median of four months before seeing a doctor about their symptoms. From that first visit, it takes about three more months to reach a suspected ALS diagnosis, then another month to confirm it. Some patients move through this process much faster, but others take well over 20 months.
Survival After Diagnosis
ALS is not only rare but also exceptionally aggressive. Median survival from the time symptoms first appear is about 30 months. Because diagnosis itself takes nearly a year on average, median survival from the point of confirmed diagnosis drops to roughly 16 months. Some people live significantly longer. In one large study, a subset of patients survived more than seven years from symptom onset, but they were the exception.
The combination of rarity, diagnostic delay, and fast progression makes ALS one of the more challenging rare diseases for both patients and researchers. Fewer cases mean smaller clinical trial pools, and shorter survival windows compress the time available to test new therapies.
Rising Case Numbers Don’t Change the Classification
ALS cases have been climbing steadily over the past four decades. Data from Denmark, where population-level tracking has been consistent since 1980, shows the number of new cases diagnosed in any four-year period has roughly tripled, from 270 cases in 1980 to 1983 up to 827 cases in 2018 to 2021. Aging populations likely account for much of this increase, since ALS risk rises with age.
Even with this upward trend, ALS remains nowhere close to crossing the 200,000-person threshold. The disease would need to become roughly six times more common than current projections suggest before losing its rare disease classification. For the foreseeable future, ALS will continue to qualify for orphan drug protections and the research funding advantages that come with them.